AnteCancerM

499.00

AnteCancerM is a set of genetic risk tests for men to assess the risk of developing prostate, colorectal cancer and melanoma. This package includes AntePC, AnteCRC and AnteMEL genetic risk tests.

What does AnteCancerM test include?

  • Analyzes of:
    • 121 genetic variants associated with prostate cancer;
    • 91 genetic variants associated with colorectal cancer;
    • 31 genetic variants associated with melanoma.
  • Personal polygenic risk score for prostate, colorectal cancer and melanoma.
  • The individual risk of:
    • prostate cancer compared to the rest of the male population;
    • colorectal cancer compared to the rest of the population;
    • melanoma compared to the rest of the population.
  • Likelihood to get:
    • prostate cancer in 10 years and risk assessment compared to a man with average genetic risk;
    • colorectal cancer in 10 years and risk assessment compared to a person with average genetic risk;
    • melanoma in 10 years and risk assessment compared to a person with average genetic risk.
  • Interpretation of the test results with clinical recommendations.
  • Genetic counseling.

Who can benefit from AnteCancerM?

Recommended for men aged 40-70 with European ancestry.

What is needed for AnteCancerM testing?

Testing requires the patient’s DNA, which is collected and isolated from the buccal swab sample (cells inside the cheek are collected with a special cotton swab).

How long does it take to get AnteCancerM test results?

Test results are available within 6 weeks from the sample being received by Antegenes.

AnteCancerM Test Limitations

  • AnteCancerM test is not used to diagnose prostate, colorectal cancer and melanoma.
  • AnteCancerM test is not validated for use by individuals of non-European descent.
  • An elevated risk estimated by the AnteCancerM test does not mean that the patient will develop prostate, colorectal cancer or melanoma during their lifetime. Also, a moderate or lower risk does not mean that the patient will not develop the diseases.
  • AnteCancerM test is patient-specific and does not assess the risk of the patient’s family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
  • AnteCancerM does not analyze rare pathogenic mutations in prostate, colorectal and melanoma genes that significantly increase the risk of developing the cancers.
  • The AnteCancerM test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
  • Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
  • The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of prostate, colorectal cancer and melanoma.

CE

AnteCancerW